EHA 2026 | Mezigdomide combinations show promising activity in relapsed/refractory multiple myeloma

Mezigdomide can be a really important solution for relapsed refractory multiple myeloma. This is a new immunomodulating agent, it is a cell modulator, and we have seen here at ASH 2026 the exciting results coming from successive clinical trials, in which me and my institution played an important role. Mezigdomide was combined with carfilzomib and dexamethasone compared with carfilzomib and dexamethasone as a control arm. And the results were exciting in terms of effectiveness, but also tolerability. The important point is that this is an oral drug, so this is manageable. People can, in some way, have a very good compliance to it. And the side effects are not particularly strong. I think that, in general, the combination is quite manageable. And I think that, even if we have an overwhelming number of drugs in the current panorama, we can imagine positioning it in second and third line considering that this is a very good option for a lenalidomide refractory and moreover that we can find a very good partner to carfilzomib also in terms of patient-reported outcomes and in general in tolerability during the treatment the combination of this new triplet is something that I have particularly appreciated. And we have also treated inside the trial some really difficult to treat patients, patients with an aggressive relapse during anti-CD38 monoclonal antibody-based treatment. And I think that we have found exciting results. So I look forward to having this triplet available also in daily practice, but I’m really happy to have contributed to this data.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.